Effect of vitamin D3 in reducing metabolic and oxidative stress in the liver of streptozotocin-induced diabetic rats.
Diabetes mellitus is a growing health problem worldwide and is associated with severe liver complications. The aim of the present study is to analyse the status of metabolic and free-radical-scavenging enzymes and second messengers in the liver of streptozotocin (STZ)-induced diabetic rats, and to determine the hepatoprotective role of vitamin D(3). All studies were performed using the liver of adult male Wistar rats. Gene expression studies were carried out using real-time PCR with specific probes. Second messenger levels were determined using (3)H-labelled Biotrak assay kits, and glucose uptake assay with D-[(14)C]glucose. The present results show that there was a decrease in hepatic glucose uptake, malate dehydrogenase activity, glycogen content, inositol triphosphate (IP(3)) and cyclic GMP levels, and superoxide dismutase, glutathione peroxidase, phospholipase C, cyclic AMP-responsive element-binding protein, vitamin D receptor (VDR) and insulin receptor (INSR) gene expression in the diabetic rats when compared with the controls (all P < 0·05), while cyclic AMP levels and GLUT2 expression were increased (P < 0·05). Treatment of the diabetic rats with vitamin D(3) and insulin reversed the altered parameters to near control values. In conclusion, the data suggest a novel role of vitamin D(3) in restoring impaired liver metabolism in STZ-induced diabetic rats by regulating glucose uptake, storage and metabolism. We demonstrated that the restoring effect of vitamin D(3) is mediated through VDR modulation, thereby improving signal transduction and controlling free radicals in the liver of diabetic rats. These data suggest a potential role for vitamin D(3) in the treatment of diabetes-associated hepatic complications.
Department of Biotechnology, St Joseph's College, Irinjalakuda              680 121, Thrissur District, Kerala, India.
Naijil
N
George
T Peeyush
TP
Kumar
Sherin
S
Antony
S
S
Jayanarayanan
C S
CS
Paulose
D000818:Animals; D002762:Cholecalciferol / Q000627:therapeutic use*; D000242:Cyclic AMP / Q000378:metabolism; D017362:Cyclic AMP Response Element-Binding Protein; D006152:Cyclic GMP / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D005609:Free Radicals / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D051273:Glucose Transporter Type 2 / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D007295:Inositol Phosphates; D007328:Insulin / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008291:Malate Dehydrogenase / Q000378:metabolism; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D011972:Receptor, Insulin / Q000378:metabolism; D018167:Receptors, Calcitriol / Q000378:metabolism*; D015398:Signal Transduction; D013482:Superoxide Dismutase / Q000378:metabolism; D010738:Type C Phospholipases / Q000378:metabolism; D014815:Vitamins / Q000627:therapeutic use*
D017362:Cyclic AMP Response Element-Binding Protein; D005609:Free Radicals; D051273:Glucose Transporter Type 2; D007295:Inositol Phosphates; D007328:Insulin; D018167:Receptors, Calcitriol; D014815:Vitamins; D002762:Cholecalciferol; D006003:Glycogen; D000242:Cyclic AMP; D008291:Malate Dehydrogenase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D011972:Receptor, Insulin; D010738:Type C Phospholipases; D006152:Cyclic GMP; D005947:Glucose